Genmab (GMAB)
(Delayed Data from NSDQ)
$21.78 USD
+0.11 (0.51%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $21.78 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth C Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Genmab A/S Sponsored ADR has a market cap of $13.90B, which represents its share price of $21.67 multiplied by its outstanding shares number of 641.54M. As a large-cap company, GMAB's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
GMAB 21.78 +0.11(0.51%)
Will GMAB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GMAB
GMAB vs. ACAD: Which Stock Is the Better Value Option?
Will Escalating Medical Costs Dampen Centene's Q2 Earnings?
GMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
Genmab (GMAB) Upgraded to Strong Buy: Here's Why
Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?
Other News for GMAB
J&J says Darzalex injectable granted EU nod for smouldering multiple myeloma
Genmab (GMAB) Reports Strong Darzalex Sales in Q2 2025
J&J boosts full-year outlook on forex tailwinds and operational performance
Genmab reports Q2 Darzalex net sales of $3.54 billion
Genmab reports Q2 worldwide net sales of Darzalex $3.54B